Roivant Sciences Ltd. — Form 10-Q Summary
Period clarification: The filing covers the three months ended June 30, 2022—Roivant’s fiscal first quarter of 2023—not 2021 Q1 as indicated in the request metadata. The comparable quarter ended June 30, 2021. Amounts below are in U.S. dollars; financial-statement amounts are converted from thousands to millions where appropriate.
Business context and reporting period
Roivant builds and operates biopharmaceutical and healthcare technology subsidiaries known as “Vants.” In May 2022, the FDA approved Dermavant’s VTAMA (tapinarof) cream for plaque psoriasis in adults, and Roivant began its first U.S. product launch. Its pipeline includes clinical-stage candidates in immunology, dermatology, oncology and other areas. The interim financial statements are unaudited.
Financial results and liquidity
| Metric | Three months ended June 30, 2022 | Three months ended June 30, 2021 |
|---|---|---|
| Revenue, net | $4.3 million | $7.7 million |
| Research and development expense | $135.8 million | $78.5 million |
| Selling, general and administrative expense | $149.1 million | $82.8 million |
| Operating loss | $282.3 million | $154.4 million |
| Net loss | $353.8 million | $101.1 million |
| Net loss attributable to Roivant | $331.8 million | $82.2 million |
| Net loss per share, basic and diluted | $0.48 | $0.13 |
| Net cash used in operating activities | $252.1 million | $141.2 million |
- Cash and liquidity: Cash and cash equivalents were $1.942 billion at June 30, 2022, down from $2.060 billion at March 31, 2022. Including restricted cash, period-end cash was $1.956 billion. Current assets were $2.039 billion and current liabilities were $328.9 million.
- Debt: Balance-sheet current and long-term debt totaled approximately $417.0 million, including debt recorded at fair value. During the quarter, Dermavant received $160 million under a tapinarof revenue-interest financing, accounted for as debt, and paid $7.3 million under the NovaQuest agreement.
- Cash flows: Investing activities used $7.5 million; financing activities provided $142.0 million, mainly reflecting the revenue-interest financing. Cash, cash equivalents and restricted cash declined by $117.6 million during the quarter.
- Margins: Revenue was not significant and the company reported an operating loss; the filing does not present a meaningful positive operating margin.
- Other balance-sheet items: Investments measured at fair value were $301.3 million. Intangible assets, principally tapinarof-related, were $145.4 million at quarter-end.
Material changes versus the prior comparable quarter
- Net loss attributable to Roivant increased by $249.6 million. Operating expenses rose $124.5 million, with R&D up $57.3 million and SG&A up $66.3 million.
- R&D growth reflected progression of programs and drug discovery, including $12.3 million for brepocitinib, higher personnel costs, and increased share-based compensation. SG&A growth largely reflected $42.9 million of additional share-based compensation and costs of the VTAMA launch.
- Operating cash use increased by $110.9 million, which management attributed mainly to advancing clinical programs and supporting the VTAMA launch.
- The quarter included $41.2 million of expense from changes in fair value of debt and liability instruments and $24.5 million of expense from investment fair-value changes. The prior-year quarter included a $66.5 million gain associated with termination of Sumitomo options, which did not recur.
- Dermavant recognized the VTAMA-related GSK regulatory milestone and Welichem sales milestone as intangible assets when achieved. The amounts owed at June 30 were included in accounts payable; they were paid in July and August 2022, respectively.
Outlook, commentary, risks and contingencies
- Management expects existing cash and cash equivalents to fund committed operating expenses and capital expenditure requirements for at least 12 months from issuance of the statements, based on current plans and forecasts. It also expects continued losses and says additional capital may be needed to implement its business plan.
- Management expects R&D and commercialization spending to rise, including spending to advance clinical programs, expand discovery efforts, and commercialize VTAMA. No quantified revenue or earnings guidance is provided.
- Management reported approximately 14,000 VTAMA prescriptions and more than 3,000 prescribers since launch, based on cited IQVIA data through early August 2022. These are management-reported launch indicators, not reported quarterly revenue guidance.
- Disclosed potential catalysts include ongoing VTAMA psoriasis launch updates; batoclimab pivotal-program activity in the second half of 2022; VTAMA atopic-dermatitis Phase 3 topline data expected in the first half of 2023; and later-stage data for other candidates in 2023–2024. Timing is subject to change and, where applicable, regulatory feedback.
- Key operating risks include uncertain commercialization and reimbursement for VTAMA, clinical and regulatory failures or delays, manufacturing and supply dependence, intellectual-property challenges, and the need for additional capital. The company reported some clinical timeline effects from COVID-19 but no material financial impact to date.
- Commitments include estimated minimum purchase obligations of $48.2 million for tapinarof supply agreements, $36.0 million for batoclimab manufacturing, and $30.0 million remaining under a Palantir software subscription. Tapinarof’s revenue-interest financing provides $160 million in return for a capped single-digit share of U.S. net sales, up to $344 million.
- Roivant and certain Immunovant officers and directors are defendants in a securities lawsuit; the company had not recorded a liability because it could not reasonably estimate losses or determine whether an unfavorable outcome was probable. Genevant and Arbutus are also defending a declaratory-judgment action brought by Acuitas relating to COVID-19 vaccine patents. The filing describes other ongoing patent proceedings and litigation risks.
- Fair-value measurements for certain investments and liabilities rely on significant unobservable inputs; changes in assumptions may materially affect reported results. Share-based compensation was $72.8 million for the quarter.
Most important facts for investors to verify
- Whether VTAMA launch prescription trends translate into sustained net sales, payer coverage and favorable net pricing; quarterly product revenue was not significant.
- The cash-burn trajectory, management’s 12-month liquidity assessment, and timing or terms of any additional financing.
- The impact of tapinarof milestone payments and revenue-interest financing on Dermavant’s future cash flows and economics.
- Clinical, regulatory and commercial progress against stated catalyst timelines, particularly VTAMA in atopic dermatitis and Immunovant’s batoclimab programs.
- Future noncash fair-value movements, dilution from equity compensation and other securities, and developments in the disclosed lawsuits and patent disputes.